Neuberger Berman Group
EGRX

Neuberger Berman Group’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Neuberger Berman Group’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-4,500
Closed -$357K – 1654
2016
Q4 		$357K Sell
4,500
-9,000
-67% -$654K ﹤0.01% 1371
2016
Q3 		$945K Buy
+13,500
New +$748K ﹤0.01% 1113
2016
Q1 		– Sell
-2,385
Closed -$211K – 1537
2015
Q4 		$211K Sell
2,385
-376
-14% -$29.7K ﹤0.01% 1440
2015
Q3 		$204K Buy
+2,761
New +$230K ﹤0.01% 1454

Other funds holding EGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Neuberger Berman Group's EGRX Position: Q1 2017 in Review

Neuberger Berman Group sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2017, closing a stake of 4,500 shares — an estimated $357K sold.

Neuberger Berman Group first reported a position in EGRX in Q3 2015 and held it in 4 quarters. The position peaked at $945K in Q3 2016. 147 funds tracked by Wall St. Rank hold EGRX as of Q1 2017.

  • Neuberger Berman Group reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • Neuberger Berman Group sold 4,500 Eagle Pharmaceuticals, Inc. shares in Q1 2017, an estimated $357K.
  • Neuberger Berman Group first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2015 and held it in 4 quarters.
  • Neuberger Berman Group's Eagle Pharmaceuticals, Inc. position peaked at $945K in Q3 2016.
  • 147 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2017.

Based on Neuberger Berman Group's 13F filing for Q1 2017, filed 10 May 2017.